Searched for
ORAL CARE PRODUCTS
U.S. drug regulator flags data integrity, maintenance lapses at Dabur India plantThe U.S. FDA has identified significant data integrity and manufacturing lapses at a Dabur India plant following a January inspection. Find...
Time to take measured and logical risks? 5 small-caps from different sectors with upside potential of up to 26%Given the fluctuating situation in the Gulf region because of the US-Iran conflict, there is no guarantee that the market will not fall fur...
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
Colgate-Palmolive India leans on premium products, advertising to drive growthColgate-Palmolive India is boosting investments in premium products and advertising. The company prioritizes volume-driven growth over marg...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 33%, according to analystsThis is easy to say, but difficult to actually implement: As an investor, make a distinction between the day-to-day movement of indices and...
Colgate-Palmolive India Q4 profit down marginally to Rs 353 cr; FY26 revenue dips to Rs 6,124 crHowever, its sales were up 9 per cent to Rs 1,582.77 crore in the March quarter of FY26. It was at Rs 1,452.02 crore in the corresponding p...
Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
For risk-takers with long-term perspective: 10 small-cap stocks from different sectors with upside potential of up to 31%If you buy small-cap stocks today, are you taking a risk or managing it? To some it might appear you are taking a risk, but there is a high...
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
These large- mid- and small-cap stocks have an upside potential of up to 31% in 1 year, according to analystsAs nothing can be ruled out on the street, be prepared for anything. Now, what is the probability that the bears will be chased away from t...
Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 31%If there is no negative development over the next few days, there is unlikely to be pressure on a large part of the market. It is, in fact,...
War, oil price hikes, and risks: Time to still be contrarian? 5 small-caps from different sectors with upside potential of up to 25%Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%In these times of geopolitical stress, how will things pan out for the Indian market? Will it be a standalone underperformer? Or is it just...